Regulatory Submission in Europe in Absence of Reference product [Regulatives / Guidelines]

posted by dshah – India, 2021-03-23 09:51 (131 d 22:01 ago) – Posting: # 22290
Views: 6,050

Hi Abhay Patil!
In absence of Innovator product in EU and UK market for FDC, you may have to do BE against individual drug substance innovator product. Please see Guideline on clinical development of fixed combination medicinal products.
Regards,
Dshah

Complete thread:

Activity
 Admin contact
21,596 posts in 4,516 threads, 1,532 registered users;
online 6 (0 registered, 6 guests [including 5 identified bots]).
Forum time: Monday 08:53 CEST (Europe/Vienna)

Imagine if every Thursday your shoes exploded
if you tied them the usual way.
This happens to us all the time with computers,
and nobody thinks of complaining.    Jef Raskin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5